For example, tumor-agnostic biomarkers such as micro-satellite instability, oncogenes like NTRK1, NTRK2, and NTRK3, and the recently United States Food and Drug Administration (FDA)-approved tumor mutation burden, are used for tumor-agnostic patient stratification and therapeutic decisions. The gene discussed is NTRK2; the disease is neoplasm.